Scalper1 News
Big-cap biotechs Celgene (CELG) and Alexion Pharmaceuticals (ALXN) were both up in the stock market today after they beat analysts’ Q3 estimates and raised their guidance. Celgene’s Q3 earnings rose 24% over the year-earlier quarter to 97 cents a share, excluding one-time items, beating analysts’ estimates by 2 cents. Sales increased 18% to $1.98 billion, about $20 million above the Street’s forecast. Celgene guided full-year revenue at $7.6 Scalper1 News
Scalper1 News